Furthermore, AS-IV has been reported to inhibit EMT and angiogenesis in gastric cancer via miR-195-5p upregulation, demonstrating its potential therapeutic role in gastric cancer via miR-195-5p-regulated PD-L1 [74]. This evidence concerns the gene CD274 and gastric cancer.